Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Clene (CLNN)
NASDAQ:CLNN
Holding CLNN?
Track your performance easily
CLNN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.82 - $12.00
Previous Close$4.01
Volume41.53K
Average Volume (3M)74.40K
Market Cap
$32.12M
Enterprise Value$34.96M
Total Cash (Recent Filing)$14.64M
Total Debt (Recent Filing)$17.61M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Mar 31, 2025EPS Estimate
-$0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding7,979,726
10 Day Avg. Volume73,173
30 Day Avg. Volume74,397
Standard Deviation0.29
R-Squared0.01
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-7.87
Price to Sales (P/S)88.33
Price to Cash Flow (P/CF)-3.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue83.05
Enterprise Value/Gross Profit65.60
Enterprise Value/Ebitda-1.15
Forecast
1Y Price Target
$48.20Price Target Upside1097.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Clene News
PremiumCompany Announcements
Clene Announces Q3 2024 Results and ALS Drug Progress
PremiumCompany Announcements
Clene Unveils Phase 3 Trial Design at NEALS
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe promising data from the RESTORE-ALS Phase 3 trial, including significant survival and functional improvements, highlight CNM-Au8's potential to become a groundbreaking treatment for ALS.
Financial PerformanceClene's recent financial results showed better-than-expected earnings per share, indicating positive financial management and potential for future growth.
Regulatory ApprovalThe potential submission of a new drug application for CNM-Au8 via the accelerated approval pathway could significantly boost investor confidence, especially given the high unmet need in ALS.
Bears Say
Financial RisksThe potential need to conduct a full Phase 3 trial prior to NDA submission could bring financing-related risks to the fore.
Regulatory ChallengesThe FDA said that the briefing package was not supportive of NDA submission via the accelerated approval pathway.
Regulatory UncertaintyIt remains very difficult to predict what the FDA might decide.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CLNN FAQ
What was Clene’s price range in the past 12 months?
Clene lowest stock price was $3.82 and its highest was $12.00 in the past 12 months.
What is Clene’s market cap?
Currently, no data Available
When is Clene’s upcoming earnings report date?
Clene’s upcoming earnings report date is Mar 31, 2025 which is in 128 days.
How were Clene’s earnings last quarter?
Clene released its earnings results on Nov 13, 2024. The company reported -$1.22 earnings per share for the quarter, beating the consensus estimate of -$1.331 by $0.111.
Is Clene overvalued?
According to Wall Street analysts Clene’s price is currently Undervalued.
Does Clene pay dividends?
Clene does not currently pay dividends.
What is Clene’s EPS estimate?
Clene’s EPS estimate is -$0.96.
How many shares outstanding does Clene have?
Clene has 7,979,726 shares outstanding.
What happened to Clene’s price movement after its last earnings report?
Clene reported an EPS of -$1.22 in its last earnings report, beating expectations of -$1.331. Following the earnings report the stock price went down -9.057%.
Which hedge fund is a major shareholder of Clene?
Currently, no hedge funds are holding shares in CLNN
---
Clene Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.20 (1097.55% Upside)
$48.20 (1097.55% Upside)
Blogger Sentiment
Bullish
CLNN Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $583.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.03%
12-Months-Change
Fundamentals
Return on Equity
-416.92%
Trailing 12-Months
Asset Growth
-47.76%
Trailing 12-Months
Company Description
Clene
Clene is a clinical-stage biopharma company focused on developing and commercializing nanotherapeutics for the treatment of neurodegenerative disease.
---
CLNN Stock 12 Month Forecast
Average Price Target
$48.20
▲(1097.55% Upside)
Technical Analysis
Annovis Bio
―
Anavex Life Sciences
―
Brainstorm Cell Therapeutics
―
Cyclacel Pharmaceuticals
―
Best Analysts Covering CLNN
1 Year
1 Year Success Rate
0/16 ratings generated profit
1 Year Average Return
-40.90%
reiterated a buy rating 10 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -40.90% per trade.
---